These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21142763)

  • 1. Seeking innovation: incentive funding for biodefense biotechs.
    Nolan JM; Samad EU; Jindra LF; Brozak SG
    Biosecur Bioterror; 2010 Dec; 8(4):365-72. PubMed ID: 21142763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NIAID Radiation Countermeasures Program business model.
    Hafer N; Maidment BW; Hatchett RJ
    Biosecur Bioterror; 2010 Dec; 8(4):357-63. PubMed ID: 21142762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Federal agency biodefense funding, FY2012-FY2013.
    Franco C; Sell TK
    Biosecur Bioterror; 2012 Jun; 10(2):162-81. PubMed ID: 22691277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Billions for biodefense: federal agency biodefense funding, FY2009-FY2010.
    Franco C
    Biosecur Bioterror; 2009 Sep; 7(3):291-309. PubMed ID: 19772453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The American biodefense industry: from emergency to nonemergence.
    Lentzos F
    Politics Life Sci; 2007 Mar; 26(1):15-23. PubMed ID: 18208342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Billions for biodefense: federal agency biodefense budgeting, FY2005-FY2006.
    Schuler A
    Biosecur Bioterror; 2005; 3(2):94-101. PubMed ID: 16000040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Greater NIH investment in family medicine would help both achieve their missions.
    Lucan SC; Bazemore AW; Xierali I; Phillips RL; Petterson SM; Teevan B
    Am Fam Physician; 2010 Mar; 81(6):704. PubMed ID: 20229969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Into the valley of death: research to innovation.
    Hudson J; Khazragui HF
    Drug Discov Today; 2013 Jul; 18(13-14):610-3. PubMed ID: 23402848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incentives for biodefense countermeasure development.
    Matheny J; Mair M; Mulcahy A; Smith BT
    Biosecur Bioterror; 2007 Sep; 5(3):228-38. PubMed ID: 17903091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Federal Agency biodefense funding, FY2011-FY2012.
    Franco C; Sell TK
    Biosecur Bioterror; 2011 Jun; 9(2):117-37. PubMed ID: 21612364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can the SBIR and STTR programs advance research goals?
    Ceulemans S; Kolls JK
    Nat Immunol; 2013 Mar; 14(3):192-5. PubMed ID: 23416667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Federal agency biodefense funding, FY2010-FY2011.
    Franco C; Sell TK
    Biosecur Bioterror; 2010 Jun; 8(2):129-49. PubMed ID: 20569055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The decline of venture capital investment in early-stage life sciences poses a challenge to continued innovation.
    Fleming JJ
    Health Aff (Millwood); 2015 Feb; 34(2):271-6. PubMed ID: 25646107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E3LSI research: an essential element of biodefense.
    Green SK
    Biosecur Bioterror; 2005; 3(2):128-37. PubMed ID: 16000044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
    Simpkin VL; Renwick MJ; Kelly R; Mossialos E
    J Antibiot (Tokyo); 2017 Dec; 70(12):1087-1096. PubMed ID: 29089600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Public funding of clinical-stage antibiotic development in the United States and European Union.
    Eichberg MJ
    Health Secur; 2015; 13(3):156-65. PubMed ID: 26042859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research funding. U.S. biodefense boom: eight new study centers.
    Malakoff D
    Science; 2003 Sep; 301(5639):1450-1. PubMed ID: 12970522
    [No Abstract]   [Full Text] [Related]  

  • 18. An audience with...Francis Collins. Interviewed by Asher Mullard.
    Collins F
    Nat Rev Drug Discov; 2011 Jan; 10(1):14. PubMed ID: 21151031
    [No Abstract]   [Full Text] [Related]  

  • 19. A Grant Framework as a Push Incentive to Stimulate Research and Development of New Antibiotics.
    Savic M; Årdal C
    J Law Med Ethics; 2018 Jun; 46(1_suppl):9-24. PubMed ID: 30146963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public funding and private investment for R&D: a survey in China's pharmaceutical industry.
    Qiu L; Chen ZY; Lu DY; Hu H; Wang YT
    Health Res Policy Syst; 2014 Jun; 12():27. PubMed ID: 24925505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.